Ray Therapeutics Appoints Dr. Peter Francis as Chief Scientific & Medical Officer and Jenny Holt as SVP, Program Portfolio Management
Ray Therapeutics Receives $4M in Funding From the California Institute for Regenerative Medicine (CIRM)
Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Ray Therapeutics closes $6M seed financing to advance novel optogenetics platform to treat blinding diseases